Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial-Reference-Cited by-同舟云学术

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Published:2017-06 Issue:10088 Volume:389 Page:2492-2502
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

El-Khoueiry Anthony B,Sangro Bruno,Yau Thomas,Crocenzi Todd S,Kudo Masatoshi,Hsu Chiun,Kim Tae-You,Choo Su-Pin,Trojan Jörg,Welling Theodore H,Meyer Tim,Kang Yoon-Koo,Yeo Winnie,Chopra Akhil,Anderson Jeffrey,dela Cruz Christine,Lang Lixin,Neely Jaclyn,Tang Hao,Dastani Homa B,Melero Ignacio

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2016

3. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability;McGlynn;Clin Liver Dis,2015

4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;J Hepatol,2012

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 3128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-02-15

2. Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-02-15

3. Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy;World Journal of Gastrointestinal Oncology;2024-02-15

4. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study;Annals of Surgical Oncology;2024-02-05

5. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma;Nature Communications;2024-02-02